Acetone → 3-Chloro-N-[1-butyl-2-(1-isopropylpiperidin-4-ylmethoxy)-ethyl]-1H-indole-6-carboxamide
反応式
[Cl:1][C:2]1[C:10]2[C:5](=[CH:6][C:7]([C:11]([NH:13][CH:14]([CH2:24][CH2:25][CH2:26][CH3:27])[CH2:15][O:16][CH2:17][CH:18]3[CH2:23][CH2:22][NH:21][CH2:20][CH2:19]3)=[O:12])=[CH:8][CH:9]=2)[NH:4][CH:3]=1.[CH3:28][C:29]([CH3:31])=O>>[Cl:1][C:2]1[C:10]2[C:5](=[CH:6][C:7]([C:11]([NH:13][CH:14]([CH2:24][CH2:25][CH2:26][CH3:27])[CH2:15][O:16][CH2:17][CH:18]3[CH2:19][CH2:20][N:21]([CH:29]([CH3:31])[CH3:28])[CH2:22][CH2:23]3)=[O:12])=[CH:8][CH:9]=2)[NH:4][CH:3]=1参加物
3
実験手順
Using alkylation method A, 3-chloro-N-[1-butyl-2-(piperidin-4-ylmethoxy)ethyl]-1H-indole-6-carboxamide (0.18 mmol) and acetone (1 mL, 14 mmol) afforded, after SCX purification, 60 mg (70%) of the title compound.
後処理
- customafforded
- customafter SCX purification, 60 mg (70%) of the title compound